FDA ap­proves first gener­ics for Take­da’s Vy­vanse as AD­HD drug short­ages per­sist

With key AD­HD med­ica­tions still in short­age, the FDA on Wednes­day ap­proved a gener­ic ver­sion of Take­da’s Vy­vanse, com­ing af­ter the name-brand drug’s patent ex­pired …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER